-
Mashup Score: 3Diabetes Dialogue: Oral GLP-1 Orforglipron in ACHIEVE-1 Trial - 15 day(s) ago
In this episode, hosts explore promising results of orforglipron, a new oral GLP-1 receptor agonist, showing significant A1C reduction and weight loss potential.
Source: www.hcplive.comCategories: General Medicine NewsTweet
-
Mashup Score: 0Diabetes Dialogue: Diabetes Tech Updates from November 2024 - 5 month(s) ago
In this episode, hosts discuss the collaboration between Dexcom and Oura Ring, expanded compatibility of Omnipod 5 with Freestyle Libre 2, and Simplera CGM integration with the InPen.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet-
In this #DiabetesDialogue, hosts discuss updates in #diabetes technology, including a collab between Dexcom and the Oura Ring, expanded compatibility of Omnipod 5 with Freestyle Libre 2 Plus, and integration between Medtronic’s Simplera CGM and InPen. https://t.co/zgKtMSpcP3
-
-
Mashup Score: 1Diabetes Dialogue: Tirzepatide’s Long-Term Obesity Data - 6 month(s) ago
In this episode, hosts explore the most recent updates surrounding GLP-1 receptor agonists, including GLP-1 shortages and long-term data on tirzepatide.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet-
In this #DiabetesDialogue, @DianaMIsaacs and @Natalie_Bellini discuss 176-week SURMOUNT data and the end of the semaglutide and tirzepatide shortages! https://t.co/cLSrItleaI #Diabetes https://t.co/HecGCmz62l
-
-
Mashup Score: 1
Brian Hansen, president of CGM at Ascensia Diabetes Care, joins the podcast to discuss the FDA clearance of the Eversense 365 CGM.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet-
Check out the latest #DiabetesDialogue! Hear from @DianaMIsaacs and @Natalie_Bellini as they interview Brian Hansen, of @AscensiaGlobal, about Eversense 365—the world's first 1-year CGM. #Diabetes https://t.co/LU7ZvryQeX https://t.co/RpxDxT9fPZ
-
-
Mashup Score: 0
Brian Hansen, president of CGM at Ascensia Diabetes Care, joins the podcast to discuss the FDA clearance of the Eversense 365 CGM.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet-
Check out the latest #DiabetesDialogue! Hear from @DianaMIsaacs and @Natalie_Bellini as they interview Brian Hansen, of @AscensiaGlobal, about Eversense 365—the world's first 1-year CGM. #Diabetes https://t.co/LU7ZvryQeX https://t.co/RpxDxT9fPZ
-
-
Mashup Score: 0
Brian Hansen, president of CGM at Ascensia Diabetes Care, joins the podcast to discuss the FDA clearance of the Eversense 365 CGM.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet-
Check out the latest #DiabetesDialogue! Hear from @DianaMIsaacs and @Natalie_Bellini as they interview Brian Hansen, of @AscensiaGlobal, about Eversense 365—the world's first 1-year CGM. #Diabetes https://t.co/LU7ZvryQeX https://t.co/RpxDxT9fPZ
-
-
Mashup Score: 5
In this episode, hosts discuss the implications of Dexcom announcing availability of their Stelo sensor and the FDA clearance of the Omnipod 5 for type 2 diabetes.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet-
This morning, we published a special edition #DiabetesDialogue with @DianaMIsaacs and @natalie_bellini bringing you their first-hand perspective after a day of using the Dexcom Stelo. Learn about their initial impressions of the device: https://t.co/PtklfJhiWr #Diabetes https://t.co/Lso3D2gGgS
-
-
Mashup Score: 5
In this episode, hosts discuss the implications of Dexcom announcing availability of their Stelo sensor and the FDA clearance of the Omnipod 5 for type 2 diabetes.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet-
This morning, we published a special edition #DiabetesDialogue with @DianaMIsaacs and @natalie_bellini bringing you their first-hand perspective after a day of using the Dexcom Stelo. Learn about their initial impressions of the device: https://t.co/PtklfJhiWr #Diabetes https://t.co/Lso3D2gGgS
-
-
Mashup Score: 0
In this episode, hosts discuss the STEP HFpEF DM trial and the need for fair allocation of incretin-based therapies with ongoing shortages and overwhelming demand.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet-
Need a breakdown of STEP HFpEF DM and what it means for providers? Check out this #DiabetesDialogue where @DianaMIsaacs and @Natalie_Bellini discuss the trial and a recent NEJM editorial on allocation of GLP-1 based therapies. https://t.co/AuGZiZaIeG #Diabetes https://t.co/CsH5qnf5K5
-
-
Mashup Score: 0
In this episode, hosts discuss the STEP HFpEF DM trial and the need for fair allocation of incretin-based therapies with ongoing shortages and overwhelming demand.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet-
Need a breakdown of STEP HFpEF DM and what it means for providers? Check out this #DiabetesDialogue where @DianaMIsaacs and @Natalie_Bellini discuss the trial and a recent NEJM editorial on allocation of GLP-1 based therapies. https://t.co/AuGZiZaIeG #Diabetes https://t.co/CsH5qnf5K5
-
In the latest #DiabetesDialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the topline results from the ACHIEVE-1 trial evaluating oral orforglipron for adults with type 2 diabetes inadequately controlled by diet and exercise. đź”—https://t.co/8N47k0w7qd #Diabetes https://t.co/Pq2lpLtbq1